By Fortune Mbonu
Japanese researchers have achieved a significant breakthrough in genetic research by using CRISPR-Cas9 to remove the extra copy of chromosome 21 associated with Down syndrome.
The study, conducted by researchers at Mie University and published in PNAS Nexus, involved laboratory-grown cells from people with Down syndrome. The technique successfully removed the extra chromosome in up to 37.5% of cells, with corrected cells showing more typical patterns of gene activity.
But the breakthrough remains firmly in the laboratory.
The researchers stressed that the technique is not ready for use in living humans. Scientists would still need to overcome major challenges, including safely delivering CRISPR to the relevant tissues, preventing unintended genetic changes and ensuring that corrected cells remain stable.
Beyond the science, the development has also renewed a long-running ethical debate. Down syndrome is associated with intellectual disability and certain health conditions, but people with Down syndrome also live, work, form relationships and participate in their communities.
For now, the Japanese study is best understood not as a cure, but as an early proof of concept that could inform future research into genetic therapies while raising difficult questions about how society approaches disability, treatment and human diversity.
